Outcomes and Treatments of Patients With Non-Small Cell Lung Cancer Who Received Pembrolizumab - PubMed
4 hours ago
- #non-small cell lung cancer
- #pembrolizumab
- #immunotherapy rechallenge
- This nationwide cohort study in France analyzed outcomes for advanced non-small cell lung cancer patients who discontinued pembrolizumab after 22-26 months of treatment.
- Among 1,480 patients with at least 6 months of follow-up, the 48-month overall survival rate after stopping pembrolizumab was 76.9%.
- After discontinuation, 26.1% of patients received subsequent therapy, primarily chemotherapy (51.7%) and radiotherapy (47.3%); immunotherapy rechallenge was rare (0.1%).
- Twelve-month overall survival rates after starting new treatment were 87.0% for radiotherapy, 69.9% for chemotherapy, and 61.4% for immunotherapy.
- The study concludes that long-term survivors have favorable survival outcomes, and rechallenge with immunotherapy after completing a 2-year course is uncommon.